Table 1.
Demographic and clinical characteristics of progressors and non-progressors in the TRuTH study at study enrolment (prognostic cohort).
| Participant characteristics | Progressors (n = 43) | Non-progressors (n = 86) | p-value | |
|---|---|---|---|---|
| Sex, n (%) | Male | 21 (49) | 42 (49) | 1.00 |
| Median age, years (range) | 35 (25–53) | 37.5 (23–62) | 1.00 | |
| Race, n (%) | Black African | 43 (100) | 85 (99) | 1.00 |
| Other | 0 (0) | 1 (1) | ||
| Median BMI, kg/m2 (range) | 24 (16.5–41.9) | 24.3 (16.4–40.8) | 0.58 | |
| Previous TB, n (%) | 1 | 27 (62.8) | 58 (67.4) | 0.56 |
| 2 | 16 (36.4) | 28 (32.6) | ||
| Median days since previous TB (range) | 876 (707–2009) | 1079 (706–1866) | <0.001 | |
| Median days on ART, (range)∗ | 758 (-22–1988) | 775.5 (-28–1803) | 0.51 | |
| Plasma viral load (pVL), copies/mL∗∗ | Undetectable, n (%) | 35 (81.4) | 79 (92.9) | 0.01 |
| Median of log dectectable pVL (range) | 4.4 (2.8–5.7) | 4.7 (3.8–6.0) | ||
| Median CD4 count (range), cells/μL | 336 (14–884) | 405 (66–1211) | 0.01 | |
∗Two non-progresors started ART after TRUTH enrollment and therefore excluded in this calculation. ∗∗Limit of detection of pVL was 400 copies/mL. Only 14 participants had detectable pVL and no formal analysis of pVL magnitude was done.